157 related articles for article (PubMed ID: 36105032)
1. Improvement and prognosis analysis of nimotuzumab combined with TP regimen induction chemotherapy and sequential concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
Luan W; Yuan H; Hou W; Li J; Liu L
Am J Transl Res; 2022; 14(8):5630-5640. PubMed ID: 36105032
[TBL] [Abstract][Full Text] [Related]
2. Effect of nimotuzumab and PF induction chemotherapy combined with concurrent chemoradiotherapy in treating locally advanced nasopharyngeal carcinoma.
Gao M; Yuan T; Zhang F
J BUON; 2021; 26(1):116-123. PubMed ID: 33721441
[TBL] [Abstract][Full Text] [Related]
3. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
[TBL] [Abstract][Full Text] [Related]
4. Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China.
Tian X; Xuan Y; Wu R; Gao S
Cancer Manag Res; 2020; 12():3323-3329. PubMed ID: 32494195
[TBL] [Abstract][Full Text] [Related]
5. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy with sequential nimotuzumab plus concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma: A retrospective real-world study.
Jiang D; Cao J; Guo L; Chen Y; Yuan G; Huang J
Medicine (Baltimore); 2023 Jan; 102(4):e32732. PubMed ID: 36705354
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma.
Liao K; Tao HY; Zhan ZJ; Qiu WZ; Zheng RH
Oncol Res Treat; 2021; 44(11):602-612. PubMed ID: 34601467
[TBL] [Abstract][Full Text] [Related]
9. An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma.
Zhang S; Huang X; Zhou L; Wu G; Lin J; Yang S; Chen J; Lin S
J BUON; 2018; 23(6):1656-1661. PubMed ID: 30610791
[TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma.
Huang J; Zou Q; Qian D; Zhou L; Yang B; Chu J; Pang Q; Wang K; Zhang F
Onco Targets Ther; 2017; 10():5835-5841. PubMed ID: 29263680
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human endostatin injection (Endostar) combined with PF chemotherapy and sequential intensity-modulated radiotherapy is tolerable and improves prognosis of locally advanced nasopharyngeal carcinoma: a randomized, open, multicenter phase II clinical study.
Xu L; Li D; Ji J; Chen Z; Tang X; Chen D; Li X; Bao D; Yan F; Pang Y; Liu S; Zhou Y; Xu X
Am J Cancer Res; 2022; 12(10):4622-4636. PubMed ID: 36381335
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].
Xie FY; Qi SN; Hu WH; Zou GR; Peng M; Li JS
Ai Zheng; 2007 Aug; 26(8):880-4. PubMed ID: 17697552
[TBL] [Abstract][Full Text] [Related]
14. The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study.
Hu J; Chen Z; Lv J; Zheng Z; Bei Y; Chen X; Zheng L; Song W; Xu Y
Front Oncol; 2022; 12():905422. PubMed ID: 35898885
[TBL] [Abstract][Full Text] [Related]
15. [Effects of Different Chemoradiotherapy Regimens on Early Survival Outcomes in Patients with Locally Advanced Nasopharyngeal Carcinoma].
Li N; Li P
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 Sep; 51(5):702-707. PubMed ID: 32975088
[TBL] [Abstract][Full Text] [Related]
16. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
[TBL] [Abstract][Full Text] [Related]
17. Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer.
Cao Y; Deng L; Lian S; Jiang Y
J BUON; 2019; 24(5):2013-2019. PubMed ID: 31786869
[TBL] [Abstract][Full Text] [Related]
18. Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis.
Wang F; Sun Q; Jiang C; Liu T; Rihito A; Masoto S; Wang Y; Fu Z; Chen M
J Cancer; 2018; 9(3):594-603. PubMed ID: 29483965
[No Abstract] [Full Text] [Related]
19. Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma: A pilot study.
Zhou L; Lin J; Chen J; Zhang S
J Cancer Res Ther; 2021 Dec; 17(7):1730-1735. PubMed ID: 35381746
[TBL] [Abstract][Full Text] [Related]
20. Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial.
Yuan JJ; Ding JW; Li JW; Hu RH; Gong D; Hu JL; Zhu KB; Liu Y; Ding YH; Wei JW; Zeng JL; Lu ZB; Yin WH; Ai SF; Zha GH; Zhang ZL; Zou R; Zeng L
BMJ Open; 2022 Aug; 12(8):e051594. PubMed ID: 36008072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
